JP2005501557A5 - - Google Patents

Download PDF

Info

Publication number
JP2005501557A5
JP2005501557A5 JP2003525634A JP2003525634A JP2005501557A5 JP 2005501557 A5 JP2005501557 A5 JP 2005501557A5 JP 2003525634 A JP2003525634 A JP 2003525634A JP 2003525634 A JP2003525634 A JP 2003525634A JP 2005501557 A5 JP2005501557 A5 JP 2005501557A5
Authority
JP
Japan
Prior art keywords
sequence
polynucleotide
vector
rna
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003525634A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005501557A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2002/009670 external-priority patent/WO2003020931A2/en
Publication of JP2005501557A publication Critical patent/JP2005501557A/ja
Publication of JP2005501557A5 publication Critical patent/JP2005501557A5/ja
Pending legal-status Critical Current

Links

JP2003525634A 2001-09-01 2002-08-29 ｓｉＲＮＡノックアウトアッセイ法およびコンストラクト Pending JP2005501557A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31722901P 2001-09-01 2001-09-01
US38573302P 2002-06-04 2002-06-04
PCT/EP2002/009670 WO2003020931A2 (en) 2001-09-01 2002-08-29 Sirna knockout assay method and constructs

Publications (2)

Publication Number Publication Date
JP2005501557A JP2005501557A (ja) 2005-01-20
JP2005501557A5 true JP2005501557A5 (enExample) 2006-01-05

Family

ID=26980845

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003525634A Pending JP2005501557A (ja) 2001-09-01 2002-08-29 ｓｉＲＮＡノックアウトアッセイ法およびコンストラクト

Country Status (8)

Country Link
US (2) US20030198627A1 (enExample)
EP (1) EP1444346B2 (enExample)
JP (1) JP2005501557A (enExample)
AT (1) ATE389016T2 (enExample)
AU (1) AU2002339458A1 (enExample)
CA (1) CA2457419A1 (enExample)
DE (1) DE60225586T3 (enExample)
WO (1) WO2003020931A2 (enExample)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
GB9925459D0 (en) * 1999-10-27 1999-12-29 Plant Bioscience Ltd Gene silencing
DE10100586C1 (de) * 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US20030084471A1 (en) * 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
US8202846B2 (en) 2000-03-16 2012-06-19 Cold Spring Harbor Laboratory Methods and compositions for RNA interference
US7423142B2 (en) * 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US7767802B2 (en) * 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
IL159756A0 (en) 2001-07-12 2004-06-20 Univ Massachusetts IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING
EP1281767A3 (en) 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
DE10163098B4 (de) 2001-10-12 2005-06-02 Alnylam Europe Ag Verfahren zur Hemmung der Replikation von Viren
DE10230997A1 (de) * 2001-10-26 2003-07-17 Ribopharma Ag Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels
US20040121348A1 (en) * 2001-10-26 2004-06-24 Ribopharma Ag Compositions and methods for treating pancreatic cancer
WO2003046186A1 (fr) * 2001-11-28 2003-06-05 Toudai Tlo, Ltd. Systeme d'expression d'arnsi et procede de production de cellule knockdown a gene fonctionnel ou analogue utilisant ce systeme
GB0130955D0 (en) * 2001-12-24 2002-02-13 Cancer Res Ventures Expression system
DE10202419A1 (de) * 2002-01-22 2003-08-07 Ribopharma Ag Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
ATE407138T1 (de) * 2002-02-14 2008-09-15 Hope City Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
WO2003093441A2 (en) 2002-05-03 2003-11-13 Duke University A method of regulating gene expression
AU2003239851A1 (en) * 2002-05-08 2003-11-11 Xantos Biomedicine Ag Expression constructs for producing double-stranded (ds) rna and the use thereof
US20030228261A1 (en) * 2002-06-05 2003-12-11 Aladar Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
EP1369491A1 (en) 2002-06-05 2003-12-10 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
JP2006500023A (ja) * 2002-09-20 2006-01-05 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ランダムＲＮＡｉライブラリーの生成法、および細胞に基づくスクリーニングにおける該ライブラリーの適用
US7892793B2 (en) 2002-11-04 2011-02-22 University Of Massachusetts Allele-specific RNA interference
US20060135453A1 (en) * 2003-01-31 2006-06-22 Jean-Charles Bologna Down-regulation of target-gene with pei/single-stranded oligoribonucleotide complexes
AU2003224132A1 (en) * 2003-04-24 2004-11-19 Galapagos Genomics N.V. Effective sirna knock-down constructs
US7524653B2 (en) * 2003-05-09 2009-04-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Small interfering RNA libraries and methods of synthesis and use
ATE485394T1 (de) 2003-06-02 2010-11-15 Univ Massachusetts Verfahren und zusammensetzungen zur verbesserung der wirksamkeit und spezifität von fnai
US7750144B2 (en) 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
US7459547B2 (en) 2003-06-02 2008-12-02 University Of Massachusetts Methods and compositions for controlling efficacy of RNA silencing
RU2376371C2 (ru) 2003-06-18 2009-12-20 Дженелюкс Корпорейшн Модифицированные рекомбинантные вакцинирующие вирусы и другие микроорганизмы и их применение
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US8680063B2 (en) 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
US20060134787A1 (en) 2004-12-22 2006-06-22 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
WO2005063983A1 (en) * 2003-12-29 2005-07-14 Galapagos Genomics N.V. Modulators of bone homeostasis identified in a high-throughput screen
PT1733056E (pt) 2004-03-31 2013-08-29 Gen Hospital Corp Método para determinar a responsividade do cancro a tratamentos visando o receptor do factor de crescimento epidérmico
DK1745295T3 (da) 2004-04-20 2011-01-31 Galapagos Nv Fremgangsmåder, sammensætninger og forbindelsesanalyser til hæmning af produktionen af amyloid beta-protein
MXPA06012162A (es) 2004-04-27 2007-03-30 Galapagos Nv Metodos, agentes y ensayos de seleccion de compuestos para inducir diferenciacion de celulas de mamifero no diferenciadas, en osteoblastos.
EP2290072B1 (en) 2004-05-28 2014-12-17 Asuragen, Inc. Methods and compositions involving microRNA
EP1773997B1 (en) 2004-06-14 2011-11-23 Galapagos N.V. Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases
US20070004658A1 (en) 2004-06-21 2007-01-04 Nick Vandeghinste Method and means for treatment of osteoarthritis
WO2006006520A1 (ja) * 2004-07-09 2006-01-19 Genofunction, Inc. 新規創薬標的の探索方法
US7485468B2 (en) * 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
US8673268B2 (en) 2004-10-15 2014-03-18 Galapagos N.V. Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
ES2534304T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
SG162726A1 (en) * 2005-05-27 2010-07-29 San Raffaele Centro Fond Gene vector comprising mi-rna
US7919583B2 (en) 2005-08-08 2011-04-05 Discovery Genomics, Inc. Integration-site directed vector systems
WO2007022470A2 (en) 2005-08-18 2007-02-22 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating neurological disease
CA2644995A1 (en) * 2006-03-07 2007-09-13 The Trustees Of The University Of Pennsylvania Random rnai libraries, methods of generating same, and screening methods utilizing same
AU2014202015B2 (en) * 2006-03-07 2016-06-02 The Trustees Of The University Of Pennsylvania Random RNAi libraries, methods of generating same, and screening methods utilizing same
FR2898908A1 (fr) 2006-03-24 2007-09-28 Agronomique Inst Nat Rech Procede de preparation de cellules aviaires differenciees et genes impliques dans le maintien de la pluripotence
AU2007253677B2 (en) * 2006-05-22 2011-02-10 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of IKK-B gene
WO2007147067A2 (en) * 2006-06-14 2007-12-21 Rosetta Inpharmatics Llc Methods and compositions for regulating cell cycle progression
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
JP2008086201A (ja) * 2006-09-29 2008-04-17 Gifu Prefecture Kenkyu Kaihatsu Zaidan マイクロｒｎａ生成の検出方法と癌の診断・治療およびマイクロｒｎａ生成調整剤
WO2008100292A2 (en) 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
US8114982B2 (en) * 2006-12-06 2012-02-14 Albert Einstein College Of Medicine Of Yeshiva University Multi-microRNA methods and compositions
WO2008156655A2 (en) 2007-06-15 2008-12-24 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
EP2162747B1 (en) 2007-06-20 2014-04-30 Galapagos N.V. Molecular targets and methods to identify compounds for treating bone and joint degenerative diseases
US8841437B2 (en) * 2008-06-20 2014-09-23 The Board Of Trustees Of The Leland Stanford Junior University Precursor miRNA loop-modulated target regulation
JP4517096B2 (ja) * 2007-07-17 2010-08-04 愛知県 癌の遺伝子治療ベクター及び癌治療用医薬組成物
EP2198050A1 (en) 2007-09-14 2010-06-23 Asuragen, INC. Micrornas differentially expressed in cervical cancer and uses thereof
WO2009054996A2 (en) * 2007-10-25 2009-04-30 Genelux Corporation Systems and methods for viral therapy
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
JP5763530B2 (ja) * 2008-06-10 2015-08-12 サンガモ バイオサイエンシーズ， インコーポレイテッド Ｂａｘ−およびＢａｋ−欠損細胞株の生成のための方法および組成物
WO2010008562A2 (en) 2008-07-16 2010-01-21 Recombinetics Methods and materials for producing transgenic animals
WO2010029118A1 (en) 2008-09-11 2010-03-18 Biofocus Dpi B.V. Method for identifying compounds useful for increasing the functional activity and cell surface expression of cf-associated mutant cystic fibrosis transmembrane conductance regulator
WO2010094732A1 (en) 2009-02-19 2010-08-26 Biofocus Dpi B.V. Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
EP2398479A2 (en) 2009-02-19 2011-12-28 Galapagos N.V. Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
US20110306655A1 (en) 2009-02-19 2011-12-15 Richard Antonius Jozef Janssen Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
WO2010115825A2 (en) 2009-03-31 2010-10-14 Robert Zimmermann Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
WO2010112569A1 (en) 2009-03-31 2010-10-07 Robert Zimmermann Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
WO2010115841A1 (en) 2009-04-01 2010-10-14 Galapagos Nv Methods and means for treatment of osteoarthritis
WO2011015573A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
WO2011015572A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
TW201120043A (en) 2009-11-05 2011-06-16 Galapagos Nv Fused pyrazine compounds as their salts, useful for the treatment of degenerative and inflammatory diseases
JP2013510564A (ja) 2009-11-13 2013-03-28 パンガエア ビオテック、ソシエダッド、リミターダ 肺癌におけるチロシンキナーゼ阻害剤に対する応答を予測するための分子バイオマーカー
US20130183326A9 (en) 2009-11-20 2013-07-18 St. Jude Children's Research Hospital Methods and compositions for modulating the activity of the interleukin-35 receptor complex
TW201129365A (en) * 2010-02-05 2011-09-01 Hoffmann La Roche Compositions and methods for inhibiting expression of IKK2 genes
JP5794558B2 (ja) * 2010-03-24 2015-10-14 国立研究開発法人産業技術総合研究所 改変された致死遺伝子及び該遺伝子を含むベクター
US8383793B2 (en) 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
ES2699630T3 (es) * 2010-04-23 2019-02-12 Cold Spring Harbor Laboratory Novedosos ARNhc diseñados estructuralmente
EP2851426B1 (en) 2010-10-18 2018-08-22 Arrowhead Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of RRM2 genes
EP2468883A1 (en) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
EP2492688A1 (en) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to antitumor treatment in lung cancer
US20140157443A1 (en) 2011-04-14 2014-06-05 St. Jude Children's Research Hospital Methods and compositions for detecting and modulating a novel mtor complex
CA2836299A1 (en) 2011-04-15 2012-10-18 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
SG194751A1 (en) 2011-06-30 2013-12-30 Arrowhead Res Corp Compositions and methods for inhibiting gene expression of hepatitis b virus
US9644241B2 (en) 2011-09-13 2017-05-09 Interpace Diagnostics, Llc Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
US20140087362A1 (en) 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
US20130280170A1 (en) 2012-04-20 2013-10-24 Aladar A. Szalay Imaging methods for oncolytic virus therapy
WO2013190089A1 (en) 2012-06-21 2013-12-27 Pangaea Biotech, S.L. Molecular biomarkers for predicting outcome in lung cancer
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
EP3279316B1 (en) 2012-11-20 2023-09-20 Phytoplant Research, S.L.U. Corticospinal upper motor neurons, methods and compositions for differentiating neural stem cells by modulating cb1 cannabinoid receptor signaling and uses thereof
WO2014139884A2 (en) 2013-03-14 2014-09-18 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrosis
JP2016522675A (ja) 2013-03-14 2016-08-04 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． 上皮間葉移行に関連した疾患の治療において有用な分子標的及び前記標的のインヒビター
EP2972322B1 (en) 2013-03-14 2019-03-06 Galapagos NV Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrotic diseases
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US11332719B2 (en) * 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
IL289396B2 (en) 2013-03-15 2023-12-01 The General Hospital Coporation Using truncated guide rnas (tru-grnas) to increase specificity for rna-guided genome editing
EP2813571A1 (en) 2013-06-13 2014-12-17 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Method for the treatment of lung cancer
WO2015051366A2 (en) 2013-10-04 2015-04-09 Novartis Ag Novel formats for organic compounds for use in rna interference
EP3052464B1 (en) 2013-10-04 2020-04-15 Novartis AG 3'end caps for rna-interferring agents for use in rna interference
CN105792832B (zh) 2013-10-04 2021-03-23 诺华股份有限公司 用于治疗乙肝病毒的有机化合物
EP3090044B1 (en) * 2013-12-26 2021-11-03 The General Hospital Corporation Multiplex guide rnas
WO2015134528A1 (en) * 2014-03-04 2015-09-11 Donald Danforth Plant Science Center New generation of artificial micrornas
CN107206088A (zh) 2014-12-05 2017-09-26 豪夫迈·罗氏有限公司 使用pd‑1轴拮抗剂和hpk1拮抗剂用于治疗癌症的方法和组合物
WO2017027350A2 (en) 2015-08-07 2017-02-16 Arrowhead Pharmaceuticals, Inc. Rnai therapy for hepatitis b virus infection
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
JOP20190015A1 (ar) 2016-08-04 2019-02-04 Arrowhead Pharmaceuticals Inc عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
CN109456995A (zh) * 2018-11-08 2019-03-12 杜以军 基因敲除质粒、细胞系及制备方法和应用
US20220356529A1 (en) 2019-07-16 2022-11-10 Université Cote D'azur Method of assessing the sensitivity or resistance of a subject to an oncolytic virus, recombinant virus, preparation and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US6060456A (en) * 1993-11-16 2000-05-09 Genta Incorporated Chimeric oligonucleoside compounds
US6146886A (en) * 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
WO1996029097A1 (en) * 1995-03-21 1996-09-26 Research Corporation Technologies, Inc. Stem-loop and circular oligonucleotides
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
EP2267138B1 (en) † 1998-04-08 2016-06-08 Commonwealth Scientific and Industrial Research Organization Methods and means for obtaining modified phenotypes
US6413776B1 (en) * 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
AU775679B2 (en) * 1998-08-20 2004-08-12 Cell Genesys, Inc. Use of suppressor tRNA's to regulate cytotoxicity during the production of recombinant gene products
WO2000049035A1 (en) * 1999-02-19 2000-08-24 The General Hospital Corporation Gene silencing
GB9904905D0 (en) * 1999-03-03 1999-04-28 Oxford Biomedica Ltd Cells
US6326193B1 (en) * 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
PT1309726E (pt) * 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
US20020132788A1 (en) * 2000-11-06 2002-09-19 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
KR100909681B1 (ko) * 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US6399378B1 (en) * 2001-03-01 2002-06-04 Isis Pharmaceuticals, Inc. Antisense modulation of RECQL2 expression
GB0118223D0 (en) * 2001-07-26 2001-09-19 Univ Sheffield Stem loop RNA
US20030148519A1 (en) * 2001-11-14 2003-08-07 Engelke David R. Intracellular expression and delivery of siRNAs in mammalian cells
US20040053876A1 (en) * 2002-03-26 2004-03-18 The Regents Of The University Of Michigan siRNAs and uses therof

Similar Documents

Publication Publication Date Title
JP2005501557A5 (enExample)
CA3219570A1 (en) Compositions and methods for improved protein translation from recombinant circular rnas
CN110959042B (zh) 一种新型小激活rna
JP2024534945A (ja) 化学修飾を有するプライム編集のためのガイドｒｎａ
WO2023222114A1 (en) Methods of making circular rna
AU2022210762A9 (en) Novel engineered and chimeric nucleases
WO2024051143A1 (zh) 利用rna连接酶制备寡核苷酸的方法
EP4269585A1 (en) Guide rna for editing polyadenylation signal sequence of target rna
CN113584027B (zh) 一种激活p21基因表达的方法
JP2005537028A5 (enExample)
US20230099592A1 (en) Novel replicase cycling reaction (rcr)
JP7807019B2 (ja) 新規なレプリカーゼサイクリング反応（ｒｃｒ）
CN112226435B (zh) 一组降低尿酸酶基因表达的核苷酸序列及应用
CN119842703B (zh) 改进的miR-OE骨架及其构建方法和应用
US20230295627A1 (en) Novel Replicase Cycling Reaction (RCR) and the Related SamRNA Designs Thereof
HK40094404A (zh) 一种新型小激活rna
EP4660306A1 (en) Artificially synthesized nucleic acid for increasing protein expression
JP4905959B2 (ja) 小分子ｒｎａの検出方法および小分子ｒｎａ検出用試薬
WO2025255168A2 (en) Modified cas12 guides and uses thereof
HK40056757A (en) Method for activating p21 gene expression
TW202606719A (zh) 新穎ｏｘｏ－ｒｎａ組合物及其相關應用
Tsai et al. NOTES & TIPS
HK40016996B (en) Novel small activating rna
HK40016996A (en) Novel small activating rna
CN121136977A (zh) Rna环化核酸分子及其应用